Brookfield Corp (BN) Stock News

BNY Mellon and State Street Corporation are both positioned as likely earnings beat candidates for Q3 2026. BNY is expected to report EPS of $2.27 (up 18.9% YoY) with an Earnings ESP of +0.33% and Zacks Rank #3, while State Street is projected to post EPS of $3.64 (up 30.9% YoY) with an Earnings ESP of +0.58% and Zacks Rank #3. Both companies have strong historical track records of beating consensus estimates.

Airbnb has been attracting investor attention with strong earnings growth expectations of 30.8% year-over-year for the current quarter and 31% for the fiscal year. The company maintains a Zacks Rank #2 (Buy) rating based on positive earnings estimate revisions. However, the stock has underperformed the S&P 500 over the past month (-5.3% vs +1.4%) and trades at a premium valuation with a D grade on the Value Style Score.

Airbnb (ABNB) has been highlighted as a solid growth stock choice, earning a Zacks Rank #2 (Buy) and Growth Score of B. The company is projected to deliver 31.1% EPS growth this year, significantly outpacing the industry average of 28.1%, with sales expected to grow 15.8% versus the industry average of 3.7%. Positive earnings estimate revisions and efficient asset utilization further support the recommendation for growth investors.

The Vanguard Total Bond Market ETF (BND) is highlighted as an attractive bond investment option, offering a yield-to-maturity of approximately 5% (the highest in nearly two decades), broad diversification across 11,400+ bonds, and an ultra-low 0.03% expense ratio. Rising interest rates have depressed bond values but increased yields, making this an opportune entry point for investors seeking fixed-income exposure and portfolio diversification.

Holzer & Holzer, LLC announced lead plaintiff deadlines for shareholder class action lawsuits against Unicycive Therapeutics, Hims & Hers Health, and Beta Bionics. The lawsuits allege materially false statements and non-disclosure of material facts regarding regulatory risks, deceptive billing practices, data sharing, and device safety issues. Investors who purchased shares during specified periods and suffered losses are encouraged to seek lead plaintiff status by November 2-3, 2026.

A class action lawsuit has been filed against Beta Bionics, Inc. (NASDAQ: BBNX) alleging securities fraud for failing to disclose material information about FDA safety violations and product issues. The company allegedly omitted over 18,000 complaints including life-threatening hypoglycemic events from FDA reports and misrepresented the severity of FDA observations. The lawsuit covers investors who purchased shares between July 30, 2025 and February 24, 2026, with a November 3, 2026 deadline to file as lead plaintiff.

A securities class action lawsuit has been filed against Beta Bionics, Inc. (NASDAQ: BBNX) alleging the company made materially false and misleading statements about its iLet Bionic Pancreas insulin pump. The FDA reportedly raised serious safety concerns including device malfunctions and dangerously high insulin dosing causing hypoglycemic events. The lawsuit claims Beta Bionics failed to implement meaningful corrective actions despite thousands of complaints. Investors who purchased stock between July 30, 2025 and February 24, 2026 may be eligible for compensation, with a November 3, 2026 deadline to serve as lead plaintiff.

Investor rights law firm Halper Sadeh LLC is investigating whether Capital Bancorp, Inc. obtained a fair price in its proposed merger with Peoples Bancorp Inc., where Capital shareholders would receive 1.11 shares of Peoples stock per share and own approximately 32% of the combined entity. The investigation examines potential breaches of fiduciary duties, fairness of the sales process, and adequacy of disclosures.

Remittix has confirmed November 24, 2026 as its RTX token launch date after raising over $32 million in presale funding. The PayFi platform is testing crypto-to-bank payments with 1,000 selected users. BNB is being analyzed for potential movement toward $1,000, while Hedera has contributed its Cross-Ledger Protocol (CLPR) to the Linux Foundation Decentralized Trust.

The article recommends the Vanguard Total Bond Market ETF (BND) as a simple, low-cost solution for bond investing. With Treasury yields hitting long-term highs and BND offering a 4.98% SEC yield with exposure to 11,421 bonds at a 0.03% expense ratio, the author advocates for regular bond purchases during periods of higher yields, viewing them as a healthy sign of economic growth rather than a warning signal.

A class action lawsuit has been filed against Beta Bionics (NASDAQ: BBNX) for investors who purchased stock between July 30, 2025 and February 24, 2026. The complaint alleges the company received thousands of complaints about serious device malfunctions in its iLet insulin pump caused by an overly aggressive dosing algorithm. The FDA issued a warning letter on February 24, 2026 detailing violations and contradicting the company's prior statements about complaint severity, leading to a 37% stock decline. The lead plaintiff deadline is November 3, 2026.

The Rosen Law Firm is reminding investors who purchased Beta Bionics common stock between July 30, 2025 and February 24, 2026 of the November 3, 2026 deadline to file a securities class action lawsuit. The lawsuit alleges that Beta Bionics made false and misleading statements about its iLet Bionic Pancreas insulin pump system, which the FDA found to have serious malfunctions causing dangerous insulin levels and hypoglycemic events. The company allegedly failed to implement corrective measures despite FDA concerns.

Beta Bionics faces a securities class action lawsuit alleging the company failed to disclose that its iLet insulin pump had a malfunctioning automated dosing algorithm causing dangerously high insulin delivery and hypoglycemic events. The company allegedly received thousands of complaints it failed to report to the FDA, and an FDA Form 483 identified over 18,000 unreported complaints. Investors with losses exceeding $100,000 have until November 3, 2026 to file lead plaintiff applications.

Rosen Law Firm is soliciting investors in Beta Bionics, Inc. (NASDAQ: BBNX) who purchased stock between July 30, 2025 and February 24, 2026 to join a securities class action lawsuit. The lawsuit alleges that Beta Bionics made materially false and misleading statements about its iLet Bionic Pancreas insulin pump, concealing that the FDA had raised serious safety concerns including device malfunctions causing dangerously high insulin dosing and thousands of complaints. The lead plaintiff deadline is November 3, 2026.

Class action lawsuits have been filed against DICK's Sporting Goods (DKS) and Beta Bionics (BBNX) for allegedly making materially false and misleading statements to investors. DKS is accused of failing to disclose issues with Foot Locker inventory and exposure to industry-wide promotional pressures. BBNX is accused of omitting FDA Form 483 safety issues and failing to disclose life-threatening complaints. Lead plaintiff deadlines are set for November 3, 2026.

BNP Paribas announced that no stabilisation activities were undertaken during the post-stabilisation period for Dolcetto Holdco S.P.A.'s EUR 490 million floating rate notes offering due July 14, 2032, which were priced at 100.

Beta Bionics (NASDAQ: BBNX) faces a securities fraud class action lawsuit after its stock dropped 37% in January 2026. The company allegedly misled investors about the safety and efficacy of its iLet insulin pump, which experienced over 18,000 unreported complaints involving life-threatening hypoglycemia. The FDA issued a warning letter citing the company's failure to report device malfunctions. Investors have until November 3, 2026 to join the lawsuit.

Robbins LLP announced a class action lawsuit against Beta Bionics, Inc. (NASDAQ: BBNX) for allegedly misleading investors about the safety and efficacy of its iLet insulin pump. The company downplayed FDA Form 483 concerns in October 2025, claiming issues were minor, but the FDA's February 2026 warning letter revealed serious malfunctions causing dangerous insulin overdoses. BBNX stock plummeted from $31.99 to $12.89 per share between January and February 2026. Investors who suffered losses during the class period (July 30, 2025 - February 24, 2026) may be eligible to recover damages.

Kirby McInerney LLP has filed securities fraud class action lawsuits against three companies. Beta Bionics faces allegations of concealing malfunctioning insulin pumps causing dangerous hypoglycemic events and FDA regulatory issues, resulting in a 37% stock decline on January 9, 2026. Lincoln Educational Services and FuelCell Energy also experienced significant stock price declines on August 10 and September 2, 2026, respectively, prompting similar legal action.

A securities class action has been filed against Beta Bionics, a medical device company, alleging that the company received thousands of complaints about serious, life-threatening hypoglycemia incidents caused by malfunctions in its iLet Bionic Pancreas insulin pump due to an overly aggressive dosing algorithm. The company allegedly failed to properly disclose these issues to investors, with the truth emerging through an FDA warning letter on February 24, 2026, following a 37% stock price decline on January 8, 2026.

A securities class action lawsuit has been filed against Beta Bionics, Inc. (NASDAQ: BBNX) alleging that the company made materially false and misleading statements about its iLet Bionic Pancreas insulin pump. The FDA reportedly raised serious safety concerns, including device malfunctions causing dangerously high insulin dosing and hypoglycemic events, with thousands of complaints filed. The company allegedly failed to implement meaningful corrective actions. Investors who purchased BBNX stock between July 30, 2025 and February 24, 2026 may be eligible for compensation, with a November 3, 2026 deadline to serve as lead plaintiff.

Apimeds Pharmaceuticals US (NYSE American: APUS), a clinical-stage biopharmaceutical company developing non-opioid therapies for pain management, has engaged IBN to enhance its corporate communications strategy. The company's subsidiary, MindWave Innovations, is developing blockchain-based institutional digital asset infrastructure combining custody, reporting, and portfolio management for Bitcoin reserves and digital asset participation.

Life Time Group Holdings (LTH) is positioned as a more attractive value investment compared to Airbnb (ABNB). LTH has a Zacks Rank of #2 (Buy) with a Value grade of B, featuring a forward P/E of 23.46 and P/B ratio of 2.76. ABNB has a Zacks Rank of #3 (Hold) with a Value grade of F, showing a forward P/E of 32.13 and P/B ratio of 12.86, indicating it is significantly more expensive on traditional valuation metrics.

Kirby McInerney LLP is alerting Beta Bionics investors about a securities fraud class action lawsuit covering the period July 30, 2025 through February 24, 2026. The lawsuit alleges the company made false statements regarding its iLet insulin pump, which was malfunctioning and dosing patients with dangerously high insulin levels. The FDA issued a Form 483 and later a warning letter citing quality management failures and lack of corrective action. The stock declined significantly following earnings misses and FDA disclosures in January and February 2026.

Rosen Law Firm has filed a class action lawsuit against Beta Bionics, Inc. (NASDAQ: BBNX) on behalf of investors who purchased common stock between July 30, 2025 and February 24, 2026. The lawsuit alleges that Beta Bionics made materially false and misleading statements about its iLet Bionic Pancreas insulin pump, which the FDA found to be malfunctioning and dosing patients with dangerously high insulin levels. The company allegedly failed to disclose thousands of complaints and hundreds of life-threatening events to the FDA. The deadline for investors to serve as lead plaintiff is November 3, 2026.

U.S. Bancorp (USB) presents a better value opportunity compared to BNY Mellon (BNY) based on valuation metrics and analyst outlook. USB has a Zacks Rank #2 (Buy) with a forward P/E of 12.05 and Value grade of B, while BNY has a Zacks Rank #3 (Hold) with a forward P/E of 17.57 and Value grade of F.

Urban Outfitters (URBN) emerges as the superior value investment compared to Ermenegildo Zegna (ZGN) based on fundamental metrics and earnings outlook. URBN holds a Zacks Rank #2 (Buy) with a Value grade of A, featuring a lower forward P/E of 12.27 and PEG ratio of 1.19, while ZGN has a Zacks Rank #3 (Hold) with a Value grade of C, showing a forward P/E of 25.79 and PEG ratio of 3.02.

Beta Bionics (NASDAQ: BBNX) is facing a securities class action lawsuit for allegedly misleading investors about its iLet automated insulin delivery system. The company concealed thousands of safety complaints, including life-threatening hypoglycemic events, and failed to report them to the FDA as required. An FDA warning letter in February 2026 revealed the violations, causing significant stock price declines during the class period of July 30, 2025 to February 24, 2026.

Barnes & Noble Education reported a Q1 loss of $0.37 per share, beating expectations of a $0.50 loss, but missed revenue estimates with $290.6 million versus the consensus estimate. Despite the revenue miss, the stock has gained 38.4% year-to-date and holds a Zacks Rank #2 (Buy) rating based on favorable estimate revisions.

Bernstein Liebhard LLP has announced multiple shareholder class action lawsuits against Beta Bionics, Dick's Sporting Goods, and EquipmentShare.com for allegedly making materially false and misleading statements regarding their business operations and financial stability. Investors who purchased shares during specified periods are encouraged to contact the firm to discuss their rights and potential recovery.